Nemtabrutinib

Generic Name: Nemtabrutinib

Clinical Trials

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

Phase 2

Not yet recruiting

Conditions: Richter Syndrome
Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma
Chronic Lymphocytic Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan
Drug: Nemtabrutinib
Biological: Pembrolizumab
Procedure: Positron Emission Tomography
Other: Questionnaire Administration

First Posted Date: 2025-03-07

Last Posted Date: 2025-03-10

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 32

Registration Number: NCT06863402

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-017)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Nemtabrutinib

First Posted Date: 2025-01-14

Last Posted Date: 2025-01-14

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 20

Registration Number: NCT06772818

Locations: 🇺🇸
Labcorp Clinical Research Unit Inc. (Site 0001), Honolulu, Hawaii, United States

A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-016)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Nemtabrutinib

First Posted Date: 2025-01-14

Last Posted Date: 2025-01-14

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 18

Registration Number: NCT06772805

Locations: 🇺🇸
Labcorp Clinical Research Unit Inc. (Site 0001), Honolulu, Hawaii, United States

A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Nemtabrutinib
Drug: Efavirenz

First Posted Date: 2024-11-20

Last Posted Date: 2024-11-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 16

Registration Number: NCT06698016

Locations: 🇺🇸
Altasciences Clinical Kansas, Inc. (Site 0001), Overland Park, Kansas, United States

A Study of the Effects of Itraconazole on the Plasma Levels of Nemtabrutinib (MK-1026-013)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Nemtabrutinib
Drug: Itraconazole

First Posted Date: 2024-11-14

Last Posted Date: 2024-11-14

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 15

Registration Number: NCT06688045

Locations: 🇺🇸
Labcorp Clinical Research Unit Inc. (Site 0001), Honolulu, Hawaii, United States

A Study of the Effect of Nemtabrutinib (MK-1026) on the Plasma Levels of Digoxin in Healthy Participants (MK-1026-012)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Digoxin
Drug: Nemtabrutinib

First Posted Date: 2024-10-03

Last Posted Date: 2024-10-03

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 24

Registration Number: NCT06625827

Locations: 🇺🇸
ICON (Site 0001), Lenexa, Kansas, United States

A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)

Phase 1

Completed

Conditions: Hematological Malignancy

Interventions: Drug: Nemtabrutinib

First Posted Date: 2024-09-06

Last Posted Date: 2024-09-09

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 40

Registration Number: NCT06586671

Locations: 🇺🇸
QPS-MRA, LLC-Early Phase (Site 0002), South Miami, Florida, United States

Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

Phase 2

Recruiting

Conditions: Mantle Cell Lymphoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Biopsy
Drug: Nemtabrutinib
Procedure: Positron Emission Tomography and Computed Tomography Scan
Biological: Rituximab

First Posted Date: 2024-08-27

Last Posted Date: 2025-03-05

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 27

Registration Number: NCT06572618

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
City of Hope at Irvine Lennar, Irvine, California, United States

A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)

Phase 1

Recruiting

Conditions: Hepatic Impairment (HI)

Interventions: Drug: Nemtabrutinib

First Posted Date: 2024-06-04

Last Posted Date: 2025-03-10

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 16

Registration Number: NCT06442436

Locations: 🇺🇸
Texas Liver Institute ( Site 0002), San Antonio, Texas, United States
🇺🇸
Clinical Pharmacology of Miami ( Site 0003), Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center ( Site 0001), Orlando, Florida, United States

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Phase 3

Recruiting

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Ibrutinib
Drug: Nemtabrutinib
Drug: Acalabrutinib

First Posted Date: 2023-11-18

Last Posted Date: 2025-05-15

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1200

Registration Number: NCT06136559

Locations: 🇺🇸
USA Mitchell Cancer Institute ( Site 0014), Mobile, Alabama, United States
🇺🇸
Florida Cancer Specialists - East ( Site 7002), West Palm Beach, Florida, United States
🇺🇸
Arizona Oncology Associates - NAHOA ( Site 8007), Prescott, Arizona, United States

and more 169 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy